UPTRAVI® (selexipag)—GRIPHON Trial Included Patients Treated With Monotherapy, Dual-, and Triple-Combination Therapy1*

Triple UP logo

THE TREATMENT EFFECT ON TIME TO FIRST DISEASE PROGRESSION EVENT WAS CONSISTENT IRRESPECTIVE OF PAH BACKGROUND THERAPY

  • 40% overall risk reduction of disease progression
UPTRAVI GRIPHON Trial Subgroup Analyses

*Dual combination with either an ERA or a PDE-5i.
Triple combination with an ERA and a PDE-5i.

Note: The figure above presents effects in various subgroups, all of which are baseline characteristics and all were prespecified; various other subgroup comparisons (not shown) were made. The 99% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.